Advanced search
Publication Cover
Expert Review of Hematology Volume 9, 2016 - Issue 2
Submit an article Journal homepage
2,038
Views
27
CrossRef citations to date
0
Altmetric
Review

Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency

M. CriscuoloHemathology Department, Catholic University of Sacred Heart, Rome, Italy
,
L. FianchiHemathology Department, Catholic University of Sacred Heart, Rome, Italy
,
G. DragonettiHemathology Department, Catholic University of Sacred Heart, Rome, Italy
&
L. PaganoHemathology Department, Catholic University of Sacred Heart, Rome, ItalyCorrespondence[email protected]
Pages 197-208 | Received 05 Sep 2015, Accepted 30 Nov 2015, Published online: 08 Jan 2016

References

  • Papers of special note have been highlighted as:
  • • of interest
  • Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61–68.
  • Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–2778.
  • Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.
  • Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–139.
  • Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol. 2001;38(4 Suppl 10):9–12.
  • Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol. 1995;12(2):129–134.
  • Wossmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82(3):160–165.
  • Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36(2):164–176.
  • Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilization and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77–83.
  • Stapleton FB, Strother DR, Roy S 3rd, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82(6):863–869.
  • Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol. 2004;17(1):50–56.
  • Vaisban E, Braester A, Mosenzon O, et al. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci. 2003;325(1):38–40.
  • Woo IS, et al. Spontaneous acute tumor lysis syndrome with advanced gastric cancer. J Korean Med Sci. 2001;16(1):115–118.
  • Feld J, Kim JS, Park MJ, et al. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. Am J Clin Oncol. 2000;23(5):491–493.
  • Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 1995;18(1):71–73.
  • Kekre N, Djordjevic B, Touchie C. Spontaneous tumour lysis syndrome. CMAJ. 2012;184(8):913–916.
  • Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.
  • Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–586.
  • Baeksgaard I, Sørensen JB. Acute tumor lysis syndrome in solid tumors–a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51(3):187–192.

• Comprehensive summary of drug associated to TLS.

  • Bedrna J, Polcák J. Acuter Harnleiter verschluss nach Bestrahlung chronischer Leukämien mit Röntgenstrahlen. Med Lin. 1929;25:1700–1701.
  • Chen SW, Hwang WS, Tsao CJ, et al. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature. J Clin Pharm Ther. 2005;30(6):623–625.
  • Seki JT, Al-Omar HM, Amato D, et al. Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Ann Pharmacother. 2003;37(5):675–678.
  • Ellis AK, Lee DH. Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera. Am J Hematol. 2002;71(3):237–238.
  • Nakhoul F, Green J, Abassi ZA, et al. Tumor lysis syndrome induced by fludarabine monophosphate: a case report. Eur J Haematol. 1996;56(4):254–255.
  • Mulligan SP, Dean MG. Fludarabine causing tumor lysis syndrome in chronic lymphocytic leukaemia. Aust N Z J Med. 1994;24:406–407.
  • List AF, Kummet TD, Adams JD, et al. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med. 1990;89(3):388–390.
  • Cheson BD, Frame JN, Vena D, et al. Tumor lysis syndrome: an uncommon complication of fludarabine therapy ofchronic lymphocytic leukemia. J Clin Oncol. 1998;16(7):2313–2320.
  • Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol. 2003;72(3):212–215.
  • Jain S, Harrison C, McMullin MF, et al. Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis. Clin Oncol (R Coll Radiol). 2010;22(10):893.
  • Schifter T, Cohen A, Lewinski UH. Severe tumor lysis syndrome following splenic irradiation. Am J Hematol. 1999;60(1):75–76.
  • Leibowitz AB, et al. Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization. Surg Laparosc Endosc Percutan Tech. 2007;17(3):210–211.
  • Lobe TE, Adamsky C, Gabrilove J, et al. Fatal refractory hyperkalemia due to tumor lysis during primary resection for hepatoblastoma. J Pediatr Surg. 1990;25(2):249–250.
  • Hunt D, Royer AM, Maxwell RA. Post splenectomy tumor lysis syndrome. J Am Surg. 2012;78(5):E299–300.
  • Lee JH, Kwon KA, Lee S, et al. Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res. 2010;34(1):e42–5.
  • Lee KD, Lee KW, Choi IS, et al. Multicentric Castleman’s disease complicated by tumor lysis syndrome. Ann Hematol. 2004;83(11):722–725.
  • Rajagopal S, Lipton JH, Messner HA. Corticosteroid induced tumor lysis syndrome in acute lymphoblastic leukemia. Am J Hematol. 1992;41(1):66–67.
  • Sparano J, Ramirez M, Wiernik PH. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin’s lymphoma. Cancer. 1990;65(5):1072–1073.
  • Dhingra K, Newcom SR. Acute tumor lysis syndrome in non-Hodgkin lymphoma induced by dexamethasone. Am J Hematol. 1988;29(2):115–116.
  • Tiley C, Grimwade D, Findlay M, et al. Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia. Leuk Lymphoma. 1992;8(1–2):143–146.
  • Lerza R, Botta M, Barsotti B, et al. Dexamethazone induced acute tumor lysis syndrome in a T-cell malignant lymphoma. Leuk Lymphoma. 2002;43(5):1129–1132.
  • Coutinho AK, De O Santos M, Pinczowski H, et al. Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol. 1997;54(1):85–86.
  • Malik IA, Abubakar S, Alam F, et al. Dexamethasone induced tumor lysis syndrome in high-grade non-Hodgkin’s lymphoma. South Med J. 1994;87(3):409–411.
  • Vaisban E, Zaina A, Braester A, et al. Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia. Ann Hematol. 2001;80(5):314–315.
  • Chanimov M, Koren-Michowitz M, Cohen ML, et al. Tumor lysis syndrome induced by dexamethasone. Anesthesiology. 2006;105(3):633–634.
  • Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62(4):247–250.
  • Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77(1–2):89–91.
  • Abou Mourad Y, Taher A, Shamseddine A. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J. 2003;4(3):222–224.
  • Jabr FI. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol. 2005;82(4):312–314.
  • Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for post transplant lymphoproliferative disorder. Transplant Proc. 2009;41(5):1946–1948.
  • Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med. 2008;3(2):161–163.
  • Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337–341.
  • Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006;7(3):233–235.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
  • Kaur V, Mehta P, Johnsurd J, et al. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood. 2014;124(23):3503–3505.
  • Ali R. Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res. 2007;31(4):573–574.
  • Vora A, Bhutani M, Sharma A, et al. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol. 2002;13(11):1833–1834.
  • Kitiyaraka C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant. 2002;17(4):685–687.
  • Dann EJ, Fineman R, Rowe JM. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol. 2002;20(1):354–355.
  • Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003;44(7):1239–1241.
  • Mahajan A, Nirmal S, English MW, et al. Acute tumor lysis syndrome in Hodgkin disease. Med Pediatr Oncol. 2002;39(1):69–70.
  • Suzuki T, Takeuchi M, Saeki H, et al. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin’s lymphoma with ABVD chemotherapy. Clin Ther. 2010;32(3):527–531.
  • Nakamura M, Oda S, Sadahiro T, et al. The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus Apher Sci. 2009;40(1):41–47.
  • Crittenden DR, Ackerman GL. Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med. 1977;137(1):97–99.
  • Rostom AY, El-Hussainy G, Kandil A, et al. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol. 2000;11(10):1349–1351.
  • Hsich PM, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol. 2009;15(37):4726–4728.
  • Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006;18(10):773–780.
  • Honda K, Saraya T, Tamura M, et al. Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma. J Clin Oncol. 2011;29(35):e859–60.
  • Castro MP, VanAuken J, Spencer-Cisek P, et al. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999;85:1055–1059.
  • Minasian LM, Szatrowski TP, Rosenblum M, et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994;83(1):56–64.
  • Stoves J, Richardson D, Patel H. Tumor lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant. 2001;16(1):188–189.
  • Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002;323(3):155–157.
  • Borne EJ, Serafi R, Piette F, et al. Tumour lysis syndrome induced by corticosteroid in metastatic melanoma presenting with initial hyperkalemia. Eur Acad Dermatol Venereol. 2009;23(7):855–856.
  • Cech P, Block JB, Cone LA, et al. Tumor lysis syndrome after tamoxifen flare. N Engl J Med. 1986;315(4):263–264.
  • Plotkin D, Lechner JJ, Jung WE, et al. Tamoxifen flare in advanced breast cancer. JAMA. 1978;240(24):2644–2646.
  • Tanvetyanon J, Choudhury AM. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. Urol. 2004;171(4):1627.
  • Pumo V, Sciacca D, Malaguarnera M. Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol. 2007;64(1):31–42.
  • Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med. 1965;62:639–647.
  • Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
  • Zusman J, Brown DM, Nesbit ME. Hyperphosphataemia, hyperphosphaturia and hypocalcaemia in acute lymphoblastic leukaemia. N Engl J Med. 1973;289(25):1335–1340.

• Identification of risk factors for TLS.

  • Arseneau JC, Canellos GP, Banks PM, et al. American Burkitt’s lymphoma: A clinicopathologic study of 30 cases—I. Clinical factors relating to prolonged survival. Am J Med. 1975;58(3):314–321.
  • Montesinos P, et al. Identification of risk factors for tumour lysis syndrome in patients with acute myeloid leukemia: development of a prognostic score. Blood. 2005;106:1843a. abstr
  • Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome: A review of 37 patients with Burkitt’s lymphoma. Am J Med. 1980;68(4):486–491.
  • McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer. 1990;66(2):246–250.
  • Nomdedéu J, Martino R, Sureda A, et al. Acute tumor lysis syndrome complicating conditioning therapy for bone marrow transplantation in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant. 1994;13(5):659–660.
  • Boccia RV, Longo DL, Lieber ML, et al. Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin’s lymphoma. Cancer. 1985;56(9):2295–2297.
  • Gomez GA, Han T. Acute tumor lysis syndrome in prolymphocytic leukemia. Arch Intern Med. 1987;147(2):375–376.
  • Kunkel L, Wong A, Maneatis T, et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin’s lymphoma: a benefit-risk update. Semin Oncol. 2000;27(6 Suppl 12):53–61.
  • DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966;274(9):481–486.
  • Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med. 1975;292:626–627.
  • Darmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162(4):489–497.
  • Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93(12):1877–1885.
  • Ejaz AA, Pourafshar N, Mohandas R, et al. Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS One. 2015;10(3):e0119497.
  • Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18(8):1758–1763.

• Safety and efficacy of allopurinol.

  • Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986;109(2):292–298.
  • Navolanic PM, Pui CH, Larson RA, et al. ElitekTM- rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas, Texas, 2002. Leukemia. 2003;17(3):499–514.
  • Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol. 2011;154(1):3–13.
  • Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283(7):354–357.
  • Ablin A, Stephens BG, Hirata T, et al. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt’s lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972;21(8):771–778.
  • Shohet I, et al. Acute renal failure complicating Burkitt’s lymphoma treated with chemotherapy and allopurinol. Int J Pediatr Nephrol. 1980;1:240–241.

• Safety and efficacy of rasburicase.

  • Oda M, Satta Y, Takenaka O, et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19(5):640–653.
  • Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene. 1991;109(2):281–284.
  • Brogard JM, Coumaros D, Franckhauser J, et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol. 1972;17(9):890–895.
  • Laboureur P, Langlois C. [Urate oxidase of Aspergillus flavus. I. Isolation, purification, properties]. Bull Soc Chim Biol (Paris). 1968;50(4):811–825.
  • Kissel P, Lamarche M, Royer R. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature. 1968;217(5123):72–74.
  • Masera G, Jankovic M, Zurlo MG, et al. Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr. 1982;100(1):152–155.
  • Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11(11):1813–1816.
  • Bayol A, Capdevielle J, Malazzi P, et al. Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem. 2002;36(Pt 1):21–31.
  • Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19(3):697–704.
  • Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10):2998–3003.
  • Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21(23):4402–4406.
  • Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98(5):1048–1054.
  • Ducros J, Saingra S, Rampal M, et al. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol. 1991;35(2):89–90.
  • Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother. 2003;37(7–8):1047–1054.

• Cost effectiveness of single not weight based rasburicase dosing.

  • Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with haematological malignancies (excluding Hodgkin Disease) associated with and without acute renal failure. Clin Lymphoma Myeloma. 2008;8(1):44–51.
  • Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–4213.
  • Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23:1640–1645.
  • McBride A, Lathon SC, Boehmer L, et al. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy. 2013;33(3):295–303.
  • Coutsouvelis J, Wiseman M, Hui L, et al. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol. 2013;75(2):550–553.
  • Herrington JD, Dinh BC. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. J Oncol Pharm Practice. 2015;21(2):111–117.
  • Clemmons AB, Ensley E, Hoge S, et al. Fixed-dose rasburicase in overweight and obese patients versus normal-weight patients. Ann Pharmacother. 2014;48(9):1152–1158.

• New xanthine oxidase inhibitor Febuxostat.

  • Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76:1835–1847.
  • Takai M, Yamauchi T, Fujita K, et al. Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome. Oncol Lett. 2014;8(4):1523–1527.
  • Maie K, Yokoyama Y, Kurita N, et al. Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome. SpringerPlus. 2014;3:501.
  • Spina M, Nagy Z, Ribera JM, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26:2155–2161.
  • Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest. 1977;59(5):786–793.
  • Feusner JH, Ritchey AK, Cohn SL, et al. Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol. 2008;26(34):5657–5658.
  • Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, et al. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31(1):27–28.
  • Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9(2):206–212.
  • Tsokos GC, Balow JE, Spiegel RJ, et al. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore). 1981;60(3):218–229.

• Indication for dialysis

  • Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34–38.
  • Muslimani A, Chisti MM, Wills S, et al. How we treat tumor lysis syndrome. Oncology (Williston Park). 2011;25(4):369–375.
  • Gutzwiller JP, Schneditz D, Huber AR, et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant. 2002;17(6):1037–1044.
  • Tan HK, Bellomo R, M’Pis DA, et al. Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration. Int J Artif Organs. 2001;24(4):186–191.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.